NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Bausch Health Companies Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Bausch Health Companies is a global specialty pharmaceutical and medical device company that develops and sells prescription drugs, generic medications and aesthetic devices for gastroenterology, hepatology, neurology and dermatology. Through a significant ownership stake in Bausch + Lomb, it also supplies eye health products including pharmaceuticals, contact lenses and surgical equipment. Its portfolio reaches approximately ninety countries.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bausch Health Companies Inc stock.
No reliable verdict: intrinsic value $139.55 per share, market price $8.20 (as of 2026-10-30).
Discounting its cash flows would put the shares at $139.55: 17 times the price of $8.20. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
Leak Score: 70/100 on 10 of 12 signals (Clear Leak).
All 84 Drug Manufacturers - Specialty & Generic stocks
We do not publish a verdict on BHC. Discounting its cash flows would put the shares at $139.55: 17 times the price of $8.20. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-10-30 close). Discounting its cash flows would put the shares at $139.55: 17 times the price of $8.20. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
70 out of 100, which we rate "Clear Leak", on 10 of 12 value investing signals.